Major bleeding risk in elderly patients age ≥ 75 years with non-valvular atrial fibrillation initiating oral anticoagulants: A 'real-world' comparison of warfarin, apixaban, dabigatran, or rivaroxaban

被引：0
|
作者：
Keshishian, Allison [1 ]
Kamble, Shital [1 ]
Pan, Xianying [1 ]
Burns, Leah [1 ]
Mardekian, Jack [1 ]
Horblyuk, Ruslan [1 ]
Hamilton, Melissa [1 ]
Squibb, Bristol-Myers [1 ]
机构：
[1] Bristol Myers Squibb Co, New York, NY 10154 USA
来源：
PHARMACOTHERAPY | 2016年 / 36卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
32E
引用
收藏
页码：E213 / E213
页数：1
相关论文
共 50 条
  • [1] Major bleeding risk in patients 75 years of age or older with non-valvular atrial fibrillation initiating oral anticoagulants: a real-world comparison of warfarin, apixaban, dabigatran, or rivaroxaban
    Lip, G. Y. H.
    Keshishian, A.
    Kamble, S.
    Pan, X.
    Burns, L.
    Mardekian, J.
    Horbkyuk, R.
    Hamilton, M.
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 : 500 - 501
  • [2] REAL-WORLD COMPARISON OF MAJOR BLEEDING RISK AMONG UNTREATED NON-VALVULAR ATRIAL FIBRILLATION PATIENTS AND THOSE INITIATING APIXABAN, DABIGATRAN, RIVAROXABAN, OR WARFARIN
    Amin, Alpesh
    Keshishian, Allison
    Xie, Lin
    Baser, Onur
    Price, Kwanza
    Vo, Lien
    Mardekian, Jack
    Mendoza, Mario
    Singhal, Shalabh
    Patel, Chad
    Odell, Kevin
    Trocio, Jeffrey
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 668 - 668
  • [3] Real world comparison of major bleeding risk among non-valvular atrial fibrillation patients newly initiated on apixaban, dabigatran, rivaroxaban or warfarin
    Lip, G. Y. H.
    Pan, X.
    Kamble, S.
    Kawabata, H.
    Mardekian, J.
    Masseria, C.
    Bruno, A.
    Phatak, H.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 : 1085 - 1085
  • [4] BLEEDING RISK AMONG JAPANESE NON-VALVULAR ATRIAL FIBRILLATION PATIENTS INITIATED ON APIXABAN, DABIGATRAN, RIVAROXABAN OR WARFARIN IN THE REAL WORLD
    Wang, Feng
    Murata, Tatsunori
    Izumi, Naoko
    Kida, Makoto
    Horblyuk, Ruslan
    Terayama, Yasuo
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 443 - 443
  • [5] Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin A propensity score matched analysis
    Lip, Gregory Y. H.
    Keshishian, Allison
    Kamble, Shital
    Pan, Xianying
    Mardekian, Jack
    Horblyuk, Ruslan
    Hamilton, Melissa
    [J]. THROMBOSIS AND HAEMOSTASIS, 2016, 116 (05) : 975 - 986
  • [6] Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
    Tepper, Ping G.
    Mardekian, Jack
    Masseria, Cristina
    Phatak, Hemant
    Kamble, Shital
    Abdulsattar, Younos
    Petkun, William
    Lip, Gregory Y. H.
    [J]. PLOS ONE, 2018, 13 (11):
  • [7] Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States
    Lip, Gregory Y. H.
    Pan, Xianying
    Kamble, Shital
    Kawabata, Hugh
    Mardekian, Jack
    Masseria, Cristina
    Bruno, Amanda
    Phatak, Hemant
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2016, 70 (09) : 752 - 763
  • [8] REAL-WORLD COMPARISON OF MAJOR BLEEDING AND ASSOCIATED COSTS AMONG ORAL ANTICOAGULANT-NAIVE NON-VALVULAR ATRIAL FIBRILLATION PATIENTS INITIATING APIXABAN, DABIGATRAN, RIVAROXABAN, OR WARFARIN IN THE US MEDICARE POPULATION
    Amin, Alpesh
    Keshishian, Allison
    Trocio, Jeffrey
    Le, Hannah
    Dina, Oluwaseyi
    Qisu, Zhang
    Baser, Onur
    Vo, Lien
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 439 - 439
  • [9] Contemporary results from EHR study of real-world bleeding risk among elderly and overall non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, rivaroxaban and warfarin
    Lin, I.
    Masseria, C.
    Mardekian, J.
    Park, S.
    Horblyuk, R.
    Kamble, S.
    Hamilton, M.
    Abdulsattar, Y.
    Petkun, W.
    Menzin, J.
    Lip, G. Y. H.
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 : 235 - 236
  • [10] Real-world bleeding risk among non-valvular atrial fibrillation (NVAF) patients prescribed apixaban, dabigatran, rivaroxaban and warfarin: analysis of electronic health records
    Lin, I.
    Masseria, C.
    Mardekian, J.
    Frean, M.
    Phatak, H.
    Kamble, S.
    Abdulsattar, Y.
    Petkun, W.
    Menzin, J.
    Lip, G. Y. H.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 : 1084 - 1084
12345